Gilteritinib

Definition

An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.

NCIT:C116722 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as 6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide, ASP 2215, ASP-2215, ASP2215, GILTERITINIB — per NCIT

Also identified as

ATC L01EX13 per RXNORM
NCIT NCIT:C116722 per NCIT
SCTID 782974005 per RXNORM
SCTID 782987004 per RXNORM
UNII 66D92MGC8M per RXNORM

Indications

Disease	Relation	Source
Acute myeloid leukemia	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Bone marrow	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.